The drug combination of GZ17-6.02 and bortezomib in MM cells activated ATM, the AMPK and PERK and inactivated ULK1, mTORC1, eIF2α, NFκB and the Hippo pathway (Figures 4A, 4B and 5A, 5B; Supplementary Figure 3A, 3B). The gene discussed is NFKB1; the disease is Miyoshi myopathy.